Mitobridge (acquired by Astellas)

What it was

Mitobridge was founded in 2014 to develop drugs targeting mitochondrial dysfunction across muscle, metabolic, and neurological diseases. Acquired by Astellas Pharma in 2018 for $225M upfront + milestones.

Now operates as part of Astellas’ mitochondrial-disease franchise.

Programmes

• PPARδ agonists for primary mitochondrial myopathy, ALS, Duchenne muscular dystrophy, and metabolic indications.
• Other mitochondrial-targeted pre-clinical programmes inherited by Astellas.

Why it’s in this reference

Mitobridge represents the first wave of mitochondrial-medicine biotechs to reach mainstream pharma acquisition. The thesis — that targeting mitochondrial function is a tractable drug-development strategy — has been validated commercially.

Subsequent mitochondrial-focused biotechs (Stealth BioTherapeutics, Imel Biotherapeutics, others) build on the foundation Mitobridge helped establish.

Related entries

Mitochondrial dysfunction, PGC-1α, Stealth BioTherapeutics, Sarcopenia.